In another clinical trial involving CD19/CD22 bispecific CAR-T cells for R/R B-cell lymphoma, the response rate was 87.5%, with a CR rate of 62.5% and a partial response (PR) rate of 25% [43]. This evidence concerns the gene CD22 and B-cell non-Hodgkin lymphoma.